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Background: Atrial fibrillation (AF) is the most common arrhythmia requiring treatment. High dose oral anti-arrhythmics (mainly class IC or 
quinidine) at 75% to 100% of the normal daily dose given as a single dose has been used to convert recent-onset AF. This “pill in the pocket” (PITP) 
approach has allowed some patients to treat themselves on an as needed basis for infrequent recurrences; however, pro-arrhythmic risk has limited 
the application of this approach to patients without structural heart disease (SHD). Ranolazine is an anti-anginal agent, which inhibits abnormal late 
Na+ channel currents, decreases sodium-calcium overload, potently inhibits after-depolarizations, which have been implicated in the initiation and 
propagation of AF, and has reduced pulmonary vein firing. Ranolazine has no known pro-arrhythmic affects. The ability of ranolazine to terminate AF 
in man has not been described but if useful could be a safer PITP agent with application in the presence or absence of SHD. We have studied oral 
ranolazine given as a high loading dose to convert new or paroxysmal AF. Method: 2000 mg of ranolazine were administered to 31 patients with 
new (16 patients) or paroxysmal (15 patients) AF of at least 3, but not greater than 48 hours duration. Twenty-two patients were in the hospital, 5 
in the office, and 4 at home at the time ranolazine was administered. Age, sex, echocardiographic data, associated health conditions and SHD were 
recorded. Successful conversion was defined as restoration of sinus rhythm within 6 hours of ranolazine administration. 
Results: All but 3 patients had some form of SHD and 23 had left atrial enlargement. Twenty-four of 31 patients converted to sinus rhythm. No pro-
arrhythmic effects, hemodynamic instability, adverse rate effects, or perceived intolerance (other than constipation) were noted. The 77% conversion 
rate is comparable to other reported PITP protocols and much higher than reported placebo conversion rates. 
Conclusion: High dose oral ranolazine shows utility as a possible safe agent to convert new or paroxysmal AF. Larger placebo-controlled studies 
with ranolazine as a PITP method in SHD patients seem warranted.
